AllDocs -> cancers

prostate cancer Benefits and Risks of GnRH/LHRH Agonists and Antagonists in Advanced Prostate Cancer Patients John Trachtenberg, MD Director, Prostate Cancer Princess Margaret Hospital Professor, Department of Surgery University of Toronto Toronto, Ontario, Canada Leuprolide vs Diethylstilbestrol for Metastatic Prostate Cancer Increased incidence of flare Decreased rate of initial response Better adverse event profile No difference in objective response No difference in 1-year survival Leuprolide Study Group. N Engl J Med. 1984;311(20):1281. Alternatives to Surgical Castration in the Treatment of Advanced Prostate Cancer LHRH agonists Combined androgen blockade (CAB) LHRH (GnRH) antagonists Comparison of Goserelin with Orchiectomy in Metastatic Prostate ...

1 Basis behind a Dietary Approach to combating Prostate Cancer . By John Mayes Medical Scientists are doing lots of valuable and important work, in trying to find ways to combat Prostate Cancer . Most of the work is focussing at the level of the cell and using the various techniques and the knowledge base of Molecular Biology to try and find a ‘Silver Bullet’ that will kill Prostate Cancer cells. Work on how various ligands lock into receptors to trigger CaP growth, alternative pathways for CaP activation when various antagonists are used to ‘block’ receptors, dealing with kinases that trigger growth, the role of mutated P53 genes and other factors etc. are the foci of much research. One could fill many pages just listing the various approaches and stages of sometimes quite diverse research. None of this important work while interesting, was seen by me as vital to my interests ...

A222: Prostate cancer tissues – Stage II For research use only (formalin fixed) Specifications: • No. of cases: 45 • Tissue type: Prostate cancer tissues • No. of spots: 2 spots from each cancer case (90 spots) 4 non-neoplastic spots (4 spots) • Total spots: 94 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 A222: Prostate cancer tissues – Stage II For research use only (formalin fixed) Summary of tissue spots No. Age Key Word G V Size L Z Stage 1 1, 2 59 Adenocarcinoma 6 5 2 l p 2 2 ...

prostate cancer The Instructional Innovations Lecture Series ?The Georgia Prostate Cancer Education Project: A Model for Cancer Education in Georgia ? Dabney Evans, MPH, CHES, Instructor Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University John Brunet, MLIS , Director of Multimedia Development & Distance Learning Technologies Applied Public Health, Rollins School of Public Health, Emory University Thursday, February 13, 2003 Sponsored by Centers for Disease Control and Prevention; The Rollins School of Public Health of Emory University The Emory University School of Medicine And The Nell Hodgson Woodruff School of Nursing of Emory University This month?s presentation is a presentation of a comprehensive statewide health message and professional training about prostate ...

Table 1: Average Annual Number and Percent of New Invasive Cancer Cases by Site/Type in Ohio, 1997-2001 Source: Ohio Cancer Incidence Surveillance System, Ohio Department of Health, 2004. Technical Note: Prostate cancer cases were defined as follows: International Classification of Diseases for Oncology, Third Edition (ICD-O-3), code C619, excluding histology types 9590-9989. Prostate Cancer In Ohio, 1997-2001 May 2004 This Report on Prostate Cancer Con- tains: • Case Counts and Rates by County of Residence • Age-specific Incidence Rates by Race • Proportion of Cases and Survival by Stage at Diagnosis and Race • Rates in Ohio com- pared to the US by Race • Risk Factors • Sources of Additional Information Prostate Cancer Incidence and Mortality The ...

CONTACT: Andrew Bright + 1 (484) 530 3922 andrew.bright@oncura.com www.oncura.com ONCURA™ introduces innovations in prostate cancer cryotherapy at the annual meeting of the American Urological Association Philadelphia (May 19, 2004) — As the global leader in minimally invasive prostate cancer treatment ONCURA has an extensive product development program dedicated to improving quality of life for the many men who require treatment each year. At this month’s annual meeting of the American Urological Association (AUA) in San Francisco, ONCURA introduced innovations that will increase the utility of their unique 17 gauge CryoNeedle™ technology. These innovations included an increase in the size of the therapeutic ice ball generated by their 17 gauge CryoNeedle, various other enhancements that are designed to decrease the time a patient is ...

Prostate Cancer When it comes to cancer , knowledge is good medicine. The prostate gland is one of the male sex glands. About the size of a walnut, it surrounds the neck of the bladder and the urethra (the tube that carries urine from the bladder through the penis). With the exception of skin cancer , prostate cancer is the most common cancer in men. The risk for developing prostate cancer increases with age. As men get older, the prostate may get bigger. This enlargement can block off the urethra, which can cause difficulty in urinating or may interfere with sexual function. The symptoms of an enlarged prostate may be similar to those of prostate cancer . Contact your health care provider if you have any of the following symptoms: • Weak or interrupted urine flow • Frequent urination, especially at night • Difficulty urinating • Pain or burning ...

Run Your Life PSA 4 P R O S T AT E S E L F A WA R E N E S S BEAT PROSTATE CANCER ! Second Annual 5K Run/Walk & 1 Mile Fun Walk To Benefit Prostate Cancer Research and Awareness FATHER’S DAY 8:30 am Sunday, June 20, 2004 P hiladelphia Art Museum – Eakins Oval USA Track and Field Certified Course Presented by Breast Health Institute A Division of the Foundation for Breast and Prostate Health

he Prostate Cancer Foundation is dedicated to finding better treatments and a cure for prostate cancer . Prostate cancer is the most common non- skin cancer in America, striking over 230,000 new men each year. One in six men will get prostate cancer . A man is one third more likely to get prostate cancer than a woman is to get breast cancer . As the baby boomer men reach the target zone for prostate cancer , beginning at age 50, the number of new cases is projected to increase dramatically. By 2015, there will be more than 300,000 new prostate cancer cases each year, a 50% increase. For the past decade, the Prostate Cancer Foundation has been working tirelessly to prevent this tragedy. When we began, efforts to find a cure were at a standstill. Scientists had few sources of funding ...

10 Few people realise that the number of men killed by prostate cancer is almost equal to the number of women killed by breast cancer – 10,000 per year in the UK as opposed to 13,000 – and far more than the number of women killed by cervical cancer . Prostate cancer strikes one man in thirteen in a lifetime, and it kills half its victims. It has increased in frequency in recent years; yet, surprisingly, government money put into dealing with prostate cancer is only a fraction of that put into women’s cancers. The prostate gland is an organ about the size of a walnut surrounding the upper part of the urethra, the duct that takes urine from the bladder. The gland provides fluids that form part of the semen. It generally grows larger in later life and it is common for men in later life to experience some restric- tion of their ...

Visualizing Prostate Cancer Patients Treated with Three- Dimensional Computed Tomography-Guided Brachytherapy Jee Vang Faleh Al-Shameri May 5, 2003 Page 2 Background on Prostate Cancer Most common cancer among US men In year 2002 189,000 US men diagnosed with prostate cancer (of which) 30,200 died from prostate cancer Risk factors Age: White male over 50, Black male at 40 Race: Black male have incidence 1.5 times white male (China and Japan lowest) Family History: Male with first-degree relative with prostate cancer has twice increased risk for prostate cancer Page 3 Clinical Indicators of Prostate Cancer Prostate -specific antigen (PSA) Continuous value (above 0.0) Gleason’s score Whole ...

A fact sheet from the Greater Bay Area Cancer Registry Prostate Cancer in the Greater San Francisco Bay Area 1988-2000 Spring 2004 In men, prostate cancer is the most common type of cancer diagnosed, comprising almost a third of all cancer cases. Nearly 50,000 men were diagnosed with prostate cancer in the Greater Bay Area during the period 1988-2000, an average of 4,000 cases per year. Prostate cancer is also a leading cause of cancer death in men, second only to lung cancer . Figure 1. Age-adjusted incidence and mortality rates for prostate cancer by year of diagnosis, Greater San Francisco Bay Area, 1988-2000 Figure 2. Age-adjusted prostate cancer incidence by race/ethnicity, Greater San Francisco Bay Area, 1988-2000 0 25 50 75 100 125 150 175 200 225 ...

Cryotherapy Simulator for Localized Prostate Cancer James K. Hahn, Ph.D. 1 , Michael J. Manyak, M.D. 2 , Ge Jin 1 , Dongho Kim 1 , John Rewcastle, Ph.D. 3 , Sunil Kim, Ph.D. 4 , and Raymond J. Walsh, Ph.D. 2 1 Institute for Computer Graphics 2 Department of Urology , School of Medicine and Health Sciences The George Washington University 3 Department of Radiology, University of Calgary and Endocare Inc. 4 Department of Biomedical Engineering, Hanyang University Abstract . Cryotherapy is a treatment modality that uses a technique to selectively freeze tissue and thereby cause controlled tissue destruction. The procedure involves placement of multiple small diameter probes through the perineum into the prostate ...

Providing access to the latest information on health-related funding opportunities Prostate Cancer 11 May 2004 Page 2 www.rdinfo.org.uk Each issue contains the following information for each funding body. The contact name and phone number of the charity or funding organisation The aim of the organisation with reference to research funding. The name of the individual awards or calls for funding. The contact details of the individual award, if it is different from the main contact details of the organisation The amount of funding available. Specific aims of the individual grant. Any restriction(s) which apply. The details shown in this bulletin is a sub-set of the information contained in the main RDInfo database, which can be viewed from the website. RDInfo is funded by the Department of Health to provide quick and easy access to all health-related ...

P1: FHD/GCX/LOV P2: GVG/LOV QC: Journal of Medical Systems [joms] pp581-joms-376999 September 19, 2002 12:59 Style file version June 5th, 2002 Journal of Medical Systems, Vol. 27, No. 1, February 2003 ( C 2003) An e-Learning Caregiving Program for Prostate Cancer Patients and Family Members Janet Reis, 1,4 Brendan McGinty, 2 and Sandi Jones 3 e-health interventions have the potential to augment caregiving training for manage- ment of chronic disease. Instruction on caregiving functions often key to patients and families’ well being is time consuming but not reimbursable in our current health care system. A theoretically defined interactive multimedia program is described which would assess patient and family member’s level of preparedness for specific caregiving functions for ...

C RYOSURGERY AND B RACHYTHERAPY VOL. 6 SUPPL. 4 2004 REVIEWS IN UROLOGY S3 Minimally Invasive Therapy for Prostate Cancer : Use of Nomograms to Counsel Patients About the Choice and Probable Outcome of Therapy Kevin M. Slawin, MD,* Christopher J. DiBlasio, MD, † Michael W. Kattan, PhD ‡ *Baylor Prostate Center, The Scott Department of Urology, Baylor College of Medicine, Houston, TX; † Department of Surgery, University of Tennessee, Memphis, TN; ‡ Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY Despite dramatic and recently accelerated advances in the reduction of morbidity linked to radical prostatectomies, significant short- and long-term morbidity is still associated with this ...

Current Cancer Drug Targets , 2004, 4, 1-11 1 1568-0096/04 $45.00+.00 © 2004 Bentham Science Publishers Ltd. Prostate Cancer Prevention by Silibinin Rana P. Singh 1 and Rajesh Agarwal *1,2 1 Department of Pharmaceutical Sciences, School of Pharmacy, 2 University of Colorado Cancer Center, Denver, CO 80262, USA. University of Colorado Health Sciences Center, Denver, CO 80262, USA Abstract: Several epigenetic alterations leading to constitutively active mitogenic and cell-survival signaling, and loss of apoptotic response are causally involved in self-sufficiency of prostate cancer (PCA) cells toward uncontrolled growth, and increased secretion of pro-angiogenic factors. Therefore, one targeted approach for PCA prevention, growth control and/or treatment could be inhibition of epigenetic molecular events ...

Current Cancer Drug Targets , 2004, 4, 85-95 85 1568-0096/04 $45.00+.00 © 2004 Bentham Science Publishers Ltd. Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy Jason B. Garrison and Natasha Kyprianou * Division of Urology, Department of Surgery and Departments of Molecular and Cellular Biochemistry, and Pathology & Laboratory Medicine, University of Kentucky Medical Center, Lexington, KY, USA Absract: Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patient’s age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving the survival and quality of life in patients with advanced prostate cancer . Apoptosis as a genetically regulated ...

Provided as an educational service by Visit our Web site at www.prostateinfo.com AstraZeneca Pharmaceuticals LP 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 ZOLADEX is a registered trademark of the AstraZeneca group of companies. © 2002 AstraZeneca Pharmaceuticals LP. All rights reserved. Printed in USA 207051 06/02 What you should know about Prostate Cancer Visit our web site at www.prostateinfo.com Q u e s t i o n s & A n s w e r s Page 2 Prostate cancer is a big public health concern. Every 3 minutes a man is diagnosed with prostate cancer in the United States. Public awareness about prostate cancer , in general, is growing. We hope that this brochure will answer some of your questions about prostate cancer and ...

Red Wine May Keep Prostate Cancer Cells in Check Tue Jul 9,12:31 PM ET NEW YORK (Reuters Health) - Compounds in red wine may keep prostate cancer cells from proliferating, results of a preliminary laboratory study suggest. Researchers from Spain found five different polyphenols--antioxidants found in red wine, tea, and certain fruits and vegetables--inhibited the growth of prostate cancer cells in a test tube and encouraged cancer cells to "commit suicide"--a natural process called apoptosis. The findings, if confirmed by larger studies, may help to explain the higher rates of prostate cancer in the US and non-Mediterranean European countries, according to Dr. I. Romero and colleagues from Getafe University in Madrid, Spain. The rate of prostate cancer in Mediterranean countries, where intake of red wine and other polyphenol- containing foods is high, ...

Kalamazoo County Human Services Department Volume I ? Number 4 www.kalcounty.com July 2002 Prostate Cancer in Kalamazoo County ? In 1999, 148 cases of prostate cancer were diagnosed in Kalamazoo County residents (Table 1). The average number of cases decreased in the later part of the 1990s from an average of 187 cases in 1990-94 to 140 cases in 1995-99. ? The age-adjusted incidence rates of prostate cancer decreased during the later part of the 1990s (Figure 1). In 1999 the county rate was 17.6 and the state rate was 20.1. ? Twenty-six deaths in the county were attributed to prostate cancer during 2000 (Table 1). ? In 2000 the prostate cancer mortality rate in the county was 3.2 per 10,000 compared to the Michigan rate of 3.9 per 10,000 (Figure ...

CANCER CONNECT PROSTATE Would you like more information? Linking People through their experience of Cancer CANCER ACTION CANCER HELP LINE Please contact: GROUP Trevor and Coralie Hunt 131120 (S.A.) Inc. (Morphett Vale) Phone 8381 9771 Promoting awareness and http://www.cancersa.org.au Jeff and Theban Roberts information for men and (Internet) (Daw Park) their families who are chl@cancersa.org.au (email) Phone 8277 3424 concerned about prostate cancer . Ray Power PROSTATE CANCER (West Lakes) FOUNDATION OF AUSTRALIA Phone 8356 9887 1800 22 00 99 http://www. prostate .org.au ...

127 Foods and Prostate Cancer Survival Many research studies have shown how foods affect the risk of developing prostate cancer . Vegetables and fruits reduce the risk, while dairy products and fatty foods appear to increase it. But what about after prostate cancer has been diagnosed? Will a change in eating habits help a man beat the disease? More research is needed, but evidence already available suggests that, whatever other treatments a man may undergo, changes in his diet might well save his life. The first clues that diet could make a big difference in survival emerged from international comparisons in the 1970s. A man in Hong Kong, where diets are rich in rice and vegetables, is half as likely to have cancerous cells in his prostate , compared to a man in Sweden, where diets are high in dairy products and meat. But if cancer happens to strike, a man in Hong Kong ...

103 Proclamations Proc. 7700 before we can reliably detect the disease in its earliest stages when treat- ment is most effective. I urge all women to talk to their doctors about ovar- ian cancer and the best course of action to detect and treat this deadly dis- ease. Doing so is particularly important for women aged 40 or older, those with a family history of ovarian cancer , and those with a personal history of breast, endometrial, or colon cancer . And I urge individuals across the country to learn more about this disease and what can be done to reduce the number of individuals who suffer from it. In addition to encouraging early detection and increasing awareness about ovarian cancer , we must continue to advance our knowledge through re- search. Scientists at the Centers for Disease Control and Prevention, the Na- tional Cancer Institute, the Department of Defense, the ...

Symptoms of Prostate Cancer In many cases, there are no symptoms associated with prostate cancer . The disease is often diagnosed as a result of a routine blood test. If symptoms are present, they are not specifi c to prostate cancer . Please note that this list of symptoms is not intended to help you diagnose yourself with prostate cancer . There are many other reasons to have each of these symptoms. However, if you do have any of these symptoms, you should consult your doctor. During Urination (peeing): Frequent urination Urinating (peeing) more often than is usual for you. Weak urine stream The fl ow of urine you produce is less powerful than is usual for you. Diffi culty starting urination It takes a long time, or is uncomfortable/painful for you to start to urinate. Burning sensation You feel a burning sensation when ...

prostate cancer THE NCRI?s SOUTH OF ENGLAND PROSTATE CANCER RESEARCH COLLABORATIVE CALL FOR PROPOSALS The National Cancer Research Institute?s (NCRI?s) South of England Prostate Cancer Research Collaborative is inviting bids for pilot and development awards. The aim of the Collaborative, which is jointly funded by the MRC, Cancer Research UK and Department of Health, is to set up research in three broad translational research areas: (A) Molecular Pathology of Prostate Cancer ; (B) Novel Therapies for Prostate Cancer ; and (C) Aetiology of Prostate Cancer . Successful applications would be expected, where appropriate, to link to these initiatives and direct their research towards the overall aims of improving the treatment of this disease and increasing the understanding of its mechanism of development. The awards are designed ...

Prostate Cancer Overview NYCRIS 04/03/04 09:38 Page 1 of 3 Prostate Cancer Overview Prostate cancer is now the most commonly diagnosed cancer in men in the UK; with around 24,700 new cases per year, and with approximately 9,900 deaths per year it is the second most common cause of cancer deaths in men 1 . Survival from prostate cancer has greatly improved since the 1970s, and rates now stand at 84%, 60% and 28% at one, five and ten years respectively 1 . Part of the reason for the improved survival is the huge increase in patients presenting with early stage over the past 10 years, resulting from prostate -specific antigen (PSA) testing and increased health education. A specific cause of prostate cancer has not been discovered, but there are many potential risk factors associated with the disease. These include hormonal influences, ...

FY03 Prostate Cancer Research Program Peer Reviewers Abdel-Mageed, Asim D.V.M., Ph.D. Department of Urology, Tulane University Health Sciences Center Adkison, Linda Ph.D. Division of Basic Medical Sciences, Mercer University School of Medicine Ahaghotu, Chiledum M.D. F.A.C.S Department of Surgery, Howard University Hospital Ahmed, Mansoor Ph.D. Department of Radiation Medicine, University of Kentucky Medical Center Arlen, Philip M.D. Laboratory of Tumor Immunology & Biology, NIH, National Cancer Institute Bahnson, Robert M.D. Division of Urology, Ohio State University College of Medicine Balk, Steven M.D., Ph.D. Hematology Oncology Division, Beth Israel Deaconess Medical Center Bartlett, Darrell American Cancer Society Batra, Surinder Ph.D. Dept of Biochemistry ...